BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38693155)

  • 1. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
    Bhattarai KR; Mobley RJ; Barnett KR; Ferguson DC; Hansen BS; Diedrich JD; Bergeron BP; Yoshimura S; Yang W; Crews KR; Manring CS; Jabbour E; Paietta E; Litzow MR; Kornblau SM; Stock W; Inaba H; Jeha S; Pui CH; Cheng C; Pruett-Miller SM; Relling MV; Yang JJ; Evans WE; Savic D
    Nat Commun; 2024 May; 15(1):3681. PubMed ID: 38693155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
    Bhattarai KR; Mobley RJ; Barnett KR; Ferguson DC; Hansen BS; Diedrich JD; Bergeron BP; Yang W; Crews KR; Manring CS; Jabbour E; Paietta E; Litzow MR; Kornblau SM; Stock W; Inaba H; Jeha S; Pui CH; Cheng C; Pruett-Miller SM; Relling MV; Yang JJ; Evans WE; Savic D
    medRxiv; 2023 Feb; ():. PubMed ID: 36798219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in acute lymphoblastic leukemia.
    Lee SHR; Yang JJ
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):229-236. PubMed ID: 29050696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
    Lugthart S; Cheok MH; den Boer ML; Yang W; Holleman A; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
    Cancer Cell; 2005 Apr; 7(4):375-86. PubMed ID: 15837626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
    Nagel S; Scherr M; Kel A; Hornischer K; Crawford GE; Kaufmann M; Meyer C; Drexler HG; MacLeod RA
    Cancer Res; 2007 Feb; 67(4):1461-71. PubMed ID: 17308084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.
    Akbari Moqadam F; Lange-Turenhout EA; Ariës IM; Pieters R; den Boer ML
    Leuk Res; 2013 Oct; 37(10):1315-21. PubMed ID: 23915977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.
    Relling MV; Ramsey LB
    Hematology Am Soc Hematol Educ Program; 2013; 2013():126-30. PubMed ID: 24319173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
    Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
    Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
    Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
    Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
    Pui CH
    Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in acute lymphoblastic leukemia.
    Cheok MH; Pottier N; Kager L; Evans WE
    Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
    Davidsen ML; Dalhoff K; Schmiegelow K
    J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood acute lymphoblastic leukemia: update on prognostic factors.
    Vrooman LM; Silverman LB
    Curr Opin Pediatr; 2009 Feb; 21(1):1-8. PubMed ID: 19242236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
    Ansari M; Krajinovic M
    Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic changes in a childhood acute lymphoblastic leukemia cell line during the adaptation to vincristine.
    Guzmán-Ortiz AL; Aparicio-Ozores G; Valle-Rios R; Medina-Contreras O; Patiño-López G; Quezada H
    Bol Med Hosp Infant Mex; 2017; 74(3):181-192. PubMed ID: 29382485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Building better therapy for children with acute lymphoblastic leukemia.
    Carroll WL; Raetz EA
    Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
    Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia.
    Bergeron BP; Diedrich JD; Zhang Y; Barnett KR; Dong Q; Ferguson DC; Autry RJ; Yang W; Hansen BS; Smith C; Crews KR; Fan Y; Pui CH; Pruett-Miller SM; Relling MV; Yang JJ; Li C; Evans WE; Savic D
    Leukemia; 2022 Oct; 36(10):2374-2383. PubMed ID: 36028659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
    Cunningham L; Aplenc R
    Expert Opin Pharmacother; 2007 Oct; 8(15):2519-31. PubMed ID: 17931087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.
    Yang H; Zhang H; Luan Y; Liu T; Yang W; Roberts KG; Qian MX; Zhang B; Yang W; Perez-Andreu V; Xu J; Iyyanki S; Kuang D; Stasiak LA; Reshmi SC; Gastier-Foster J; Smith C; Pui CH; Evans WE; Hunger SP; Platanias LC; Relling MV; Mullighan CG; Loh ML; Yue F; Yang JJ
    Nat Genet; 2022 Feb; 54(2):170-179. PubMed ID: 35115686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.